All News

An Internet-based formula often used by physicians to calculate a patient's prostate cancer risk systematically underestimates the probability that the patient may have an aggressive form of the disease, say researchers from the Stanford University School of Medicine, Stanford, CA.

A new molecular test appears to predict lymph node involvement in bladder cancer patients and may help physicians determine which patients are candidates for neoadjuvant chemotherapy, say researchers from the University of Colorado Cancer Center, Aurora.

One-fifth of cancer survivors, including those surviving prostate cancer, have current cancer-related chronic pain at least 2 years after their diagnosis, say researchers at the University of Michigan Health System, Ann Arbor.

Although rising levels of government debt create headwinds for economic growth, a country's deficit and debt levels do not seem to adversely affect capital market returns.

Researchers are working to develop a computational model that simulates the in vivo mechanical properties of the human prolapsed anterior vaginal wall to test mesh materials.

Because mesh repair after recurrence of prolapse is thought to be effective, shouldn't it be used in primary repair? A study from Dutch and Belgian researchers didn't come up with a positive answer.

The newest urology products and services from Olympus, American Medical Systems, Cook Medical, Prostrakan Group, Eli Lilly and Co., Acrux, and ForTec Medical.

Will 2011 be the year that medical malpractice reform becomes a reality? The new political alignment in Congress appears to offer more hope than in many years past, and advocates are anxious to achieve that long-elusive objective.

Results of a phase III trial failed to confirm data from a phase II study suggesting that the addition of high-dose oral calcitriol (DN-101) to docetaxel (Taxotere) confers a survival advantage and reduces toxicity versus treatment with docetaxel alone in men with progressive castration-resistant prostate cancer (CRPC).